Skip to main content

GX Sciences to Offer Patia Type 2 Diabetes Risk Test in US

NEW YORK — Spanish diabetes testing firm Patia said today that it has signed an agreement to market its type 2 diabetes (T2D) risk test in the US through GX Sciences.

The test, called DiabetesPredict, combines a genetic risk analysis with behavioral and lifestyle assessments. The genetic test uses Thermo Fisher Scientific's TaqMan OpenArray for genotyping, and includes 16 SNPs that have been associated with T2D in a variety of ethnicities, including Caucasian, Latin American, African, and Asian populations.

Under the terms of the deal, GX will market DiabetesPredict in the US and has agreed to acquire a minimum of 25,000 tests from Patia until 2021 for a minimum of €1.2 million ($1.3 million). 

According to a Patia spokesperson, the arrangement with Austin, Texas-based GX is exclusive with the exception of a deal signed last month under which Premier Medical Laboratory Services is offering DiabetesPredict in the US.

Additional terms were not disclosed.